146 related articles for article (PubMed ID: 12954496)
1. Cytokeratin 20, AN43, PGDH, and COX-2 expression in transitional and squamous cell carcinoma of the bladder.
Gee JR; Montoya RG; Khaled HM; Sabichi AL; Grossman HB
Urol Oncol; 2003; 21(4):266-70. PubMed ID: 12954496
[TBL] [Abstract][Full Text] [Related]
2. Cyclooxygenase-2 expression in urinary bladder transitional cell carcinoma and its association with clinicopathological characteristics.
Tabriz HM; Olfati G; Ahmadi SA; Yusefnia S
Asian Pac J Cancer Prev; 2013; 14(8):4539-43. PubMed ID: 24083698
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of cyclooxygenase-2 in squamous cell carcinoma of the urinary bladder.
Shirahama T; Sakakura C
Clin Cancer Res; 2001 Mar; 7(3):558-61. PubMed ID: 11297248
[TBL] [Abstract][Full Text] [Related]
4. Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder.
Ristimäki A; Nieminen O; Saukkonen K; Hotakainen K; Nordling S; Haglund C
Am J Pathol; 2001 Mar; 158(3):849-53. PubMed ID: 11238034
[TBL] [Abstract][Full Text] [Related]
5. Promoter hypermethylation of the 14-3-3 sigma, SYK and CAGE-1 genes is related to the various phenotypes of urinary bladder carcinomas and associated with progression of transitional cell carcinomas.
Kunze E; Wendt M; Schlott T
Int J Mol Med; 2006 Oct; 18(4):547-57. PubMed ID: 16964403
[TBL] [Abstract][Full Text] [Related]
6. Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder.
Shariat SF; Matsumoto K; Kim J; Ayala GE; Zhou JH; Jian W; Benedict WF; Lerner S
J Urol; 2003 Sep; 170(3):985-9. PubMed ID: 12913755
[TBL] [Abstract][Full Text] [Related]
7. [Cyclooxygenase-2-expression in bladder cancer: tumor-biological and clinical implications].
Wülfing C; Eltze E; Von Struensee D; Wülfing P; Bode ME; Bettendorf O; Piechota H; Hertle L
Aktuelle Urol; 2004 Aug; 35(4):331-8. PubMed ID: 15459875
[TBL] [Abstract][Full Text] [Related]
8. Cyclooxygenase-2 parallels invasive depth and increased MVD in transitional cell carcinoma.
Li G; Yang T; Li L; Yan J; Zeng Y; Yu J; Zhang Y
Colloids Surf B Biointerfaces; 2004 Aug; 37(1-2):15-9. PubMed ID: 15450303
[TBL] [Abstract][Full Text] [Related]
9. Loss of adipocyte-type fatty acid binding protein and other protein biomarkers is associated with progression of human bladder transitional cell carcinomas.
Celis JE; Ostergaard M; Basse B; Celis A; Lauridsen JB; Ratz GP; Andersen I; Hein B; Wolf H; Orntoft TF; Rasmussen HH
Cancer Res; 1996 Oct; 56(20):4782-90. PubMed ID: 8840999
[TBL] [Abstract][Full Text] [Related]
10. [Expression of cyclooxygenase-2 in bladder transitional cell carcinoma and the significance thereof].
Yu L; Chen XJ; Shi PQ; Ding Q; Sun CH; Liu GB; Shi DM; Huang YG
Zhonghua Yi Xue Za Zhi; 2008 Oct; 88(38):2683-4. PubMed ID: 19080686
[TBL] [Abstract][Full Text] [Related]
11. CD10 and E-cad expression in urinary bladder urothelial and squamous cell carcinoma.
Omran OM
J Environ Pathol Toxicol Oncol; 2012; 31(3):203-12. PubMed ID: 23339695
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World/Health Organization/Internattional Society of Urologic Pathology.
Alsheikh A; Mohamedali Z; Jones E; Masterson J; Gilks CB
Mod Pathol; 2001 Apr; 14(4):267-72. PubMed ID: 11301341
[TBL] [Abstract][Full Text] [Related]
13. Immunoprofile of ovarian tumors with putative transitional cell (urothelial) differentiation using novel urothelial markers: histogenetic and diagnostic implications.
Logani S; Oliva E; Amin MB; Folpe AL; Cohen C; Young RH
Am J Surg Pathol; 2003 Nov; 27(11):1434-41. PubMed ID: 14576476
[TBL] [Abstract][Full Text] [Related]
14. Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder.
Shirahama T
Clin Cancer Res; 2000 Jun; 6(6):2424-30. PubMed ID: 10873095
[TBL] [Abstract][Full Text] [Related]
15. [Expression of squamous cell carcinoma-associated antigen in bladder cancer cells--a comparative study with the expression of proliferating cell nuclear antigen (PCNA)].
Yamazaki K; Kumamoto Y; Tsukamoto T
Nihon Hinyokika Gakkai Zasshi; 1994 Apr; 85(4):589-98. PubMed ID: 7910645
[TBL] [Abstract][Full Text] [Related]
16. [Expression of cyclooxygenase in bladder transitional cell carcinoma].
Wang KJ; Li H; Wei Q; Yang YR
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Jan; 35(1):54-6. PubMed ID: 14981815
[TBL] [Abstract][Full Text] [Related]
17. Tumor markers of bladder cancer: the schistosomal bladder tumors versus non-schistosomal bladder tumors.
Abdulamir AS; Hafidh RR; Kadhim HS; Abubakar F
J Exp Clin Cancer Res; 2009 Feb; 28(1):27. PubMed ID: 19243595
[TBL] [Abstract][Full Text] [Related]
18. Urinary cytokeratin 20 as a marker for transitional cell carcinoma.
Rotem D; Cassel A; Lindenfeld N; Mecz Y; Sova Y; Resnick M; Stein A
Eur Urol; 2000 May; 37(5):601-4. PubMed ID: 10765100
[TBL] [Abstract][Full Text] [Related]
19. Cytokeratin 20 expression by non-invasive transitional cell carcinomas: potential for distinguishing recurrent from non-recurrent disease.
Harnden P; Allam A; Joyce AD; Patel A; Selby P; Southgate J
Histopathology; 1995 Aug; 27(2):169-74. PubMed ID: 8835265
[TBL] [Abstract][Full Text] [Related]
20. Transitional cell carcinomas of the ovary and bladder are immunophenotypically different.
Ordóñez NG
Histopathology; 2000 May; 36(5):433-8. PubMed ID: 10792484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
